AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Roswell Park Comprehensive Cancer Center.

    Client Virtual Booth

    ROSWELL PARK COMPREHENSIVE CANCER CENTER

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Roswell Park Comprehensive Cancer Center
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Roswell Park Comprehensive Cancer Center Elm and Carlton Streets Buffalo, NY 14263
    Telephone
    Telephone
    1-800-767-9355
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.roswellpark.org/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/roswellpark/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology ...

    Details:

    The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.


    Lead Product(s): CAR T-Cell Therapy

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy

    Recipient: Generate Biomedicines

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration November 01, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modu...

    Details:

    Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalone efficacy in a number of solid tumors.


    Lead Product(s): Rintatolimod,Interferon Alfa-2B,Paclitaxel

    Therapeutic Area: Oncology Product Name: Ampligen

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: Aim ImmunoTech

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 14, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in P...

    Details:

    Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.


    Lead Product(s): Rintatolimod,Interferon Alfa-2B,Celecoxib

    Therapeutic Area: Oncology Product Name: Ampligen

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: Aim ImmunoTech

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 30, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

    Details:

    The data, from a small number of subjects, is extremely impressive for four out of six Ampligen plus pembrolizumab patients; three demonstrated disease stabilization and one showed a significant and dramatic rapid destruction of the tumor and metastasis.


    Lead Product(s): Rintatolimod,Celecoxib,Pembrolizumab

    Therapeutic Area: Oncology Product Name: Ampligen

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: Aim ImmunoTech

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 11, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment ...

    Details:

    Primary endpoint of the study was met for Ampligen (rintatolimod), selective TLR3 ligand, evidenced by increased CD8a expression post-treatment (p=0.046), as a component of treatment for colorectal cancer metastatic to the liver.


    Lead Product(s): Rintatolimod,Celecoxib,Recombinant Interferon Alfa-2b

    Therapeutic Area: Oncology Product Name: Ampligen

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: Aim ImmunoTech

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 11, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    transo-pharm-handels-gmbh-m-2024-05-20

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search